Stockscreener 앱 받기
144.79
0.56%
0.86
전일 마감가:
$143.93
열려 있는:
$143.5
하루 거래량:
1.81M
Relative Volume:
0.25
시가총액:
$179.72B
수익:
$29.45B
순이익/손실:
$8.51B
주가수익비율:
21.35
EPS:
6.7823
순현금흐름:
$9.46B
1주 성능:
-3.53%
1개월 성능:
-4.58%
6개월 성능:
+25.03%
1년 성능:
+23.28%
1일 변동 폭
$143.49
$145.60
1주일 범위
$142.77
$148.92
52주 변동 폭
$93.37
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, NVS, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
144.77 | 178.68B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
995.76 | 884.36B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.56 | 579.34B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
225.13 | 406.87B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
160.83 | 305.53B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
193.06 | 301.19B | 58.80B | 10.24B | 8.98B | 3.2788 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Swiss National Bank Has $398 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Schroder Investment Management Group Has $230.08 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by WINTON GROUP Ltd - MarketBeat
Vinva Investment Management Ltd Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Natixis Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
B. Metzler seel. Sohn & Co. AG Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Citigroup Maintains Buy on GILD (Gilead Sciences, Inc.) March 2026 - Meyka
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $2.81 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Parallel Advisors LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Korea Investment CORP Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Rhenman & Partners Asset Management AB Sells 88,000 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Blair William & Co. IL - MarketBeat
Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Share Price Run - Yahoo Finance
Gilead’s BIC LEN HIV Results Highlight Valuation Gap And Future Potential - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Purchased by HUB Investment Partners LLC - MarketBeat
Munich Reinsurance Co Stock Corp in Munich Takes $67.50 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
First Trust Advisors LP Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences Inc. stock overvalued by current metricsWeekly Trade Review & Low Drawdown Momentum Trade Ideas - Naître et grandir
These 3 Cash Flow Machines Provide Stability in Uncertain Markets - Investing.com
BofA reiterates Gilead Sciences stock Buy rating on Yeztugo uptake - Investing.com
Gilead in talks with South Africa to start local production of new HIV therapy - Seeking Alpha
Gilead Sciences, Inc. $GILD Stock Position Lifted by Orion Porfolio Solutions LLC - MarketBeat
Kingsview Wealth Management LLC Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Edgar Lomax Co. VA Has $19.46 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Fisher Asset Management LLC - MarketBeat
South Africa seeks local production of Gilead’s HIV prevention drug - WHTC
Gilead and South Africa are negotiating a license for local production of new HIV drug - statnews.com
Stonebridge Capital Advisors LLC Sells 9,029 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now? - Yahoo Finance
South Dakota Investment Council Cuts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Picton Mahoney Asset Management Boosts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Crossmark Global Holdings Inc. Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat
South Africa seeks local production of Gilead's HIV prevention drug - marketscreener.com
Let me see you One2PrEP: Gilead campaign targets stigma with pop culture punch - Medical Marketing and Media
Griffith & Werner Inc. Makes New $1.77 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Dimensional Fund Advisors LP Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Gilead Sciences, Inc. $GILD Shares Sold by CI Investments Inc. - MarketBeat
Gilead Sciences Stock To $192? - Trefis
How Does Gilead Sciences Stock Stack Up Against Its Peers? - Trefis
Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Gilead at TD Cowen Conference: Strategic Growth and Expansion - Investing.com
Teachers Retirement System of The State of Kentucky Sells 18,145 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Victory Capital Management Inc. Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Navigates Market Shifts Within The Nasdaq Composite - Kalkine Media
Gilead Sciences (NASDAQ:GILD) Stock Acquired Rep. Josh Gottheimer - MarketBeat
Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance - Yahoo Finance
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.61%
자본화:
|
볼륨(24시간):